Quantcast

Latest Biomarker Stories

2014-10-30 08:37:13

Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers IRVING, Texas, Oct. 30, 2014 /PRNewswire/ -- Caris Life Sciences today announced the presentation of data from two large studies in which Caris Molecular Intelligence(TM), the company's panomic, comprehensive tumor profiling service, facilitated the molecular analysis of lung tumors. The biomarker...

2014-10-28 16:27:44

HILDEN, Germany and TOKYO, October 28, 2014 /PRNewswire/ -- - First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development - QIAGEN Personalized Healthcare pipeline expands with novel assay targeting FGFR mutations - Partnership provides options for collaboration across therapeutic areas, sample types and testing technologies QIAGEN N.V. (NASDAQ: QGEN; Frankfurt...

2014-10-28 12:31:20

DENVER, Oct. 28, 2014 /PRNewswire/ -- Pharmatech seeking biomarker targeting lung cancer studies. Following the successful launch of AccessPPM, Pharmatech has begun its series of clinical trials in a portfolio of studies planned to treat the different molecular drivers of lung cancer. This approach, which will also be applied for other types of cancer, is designed to identify all of a patient's active biomarkers up front, then provide immediate access to research based treatment...

2014-10-28 12:30:50

TUCSON, Ariz., Oct. 28, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1)...

2014-10-28 08:36:43

HEIDELBERG, Germany, Oct. 28, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that the final data of the completed phase II clinical trial with APG101 in recurrent glioblastoma has been published in the peer-reviewed journal Clinical Cancer Research. The data demonstrates that treatment with APG101, a CD95 ligand-binding fusion protein, in combination with radiotherapy is an innovative concept that has shown clinical superiority in all study...

2014-10-28 00:28:46

LONDON, Oct. 27, 2014 /PRNewswire/ -- The immunoassay market is large and long-established, but at the same time highly competitive. Kalorama Information's newly published report, The World Market for Immunoassays, describes the opportunities that exist for large IVD companies adopting new strategies and for new entrants to take market share. Immunoassays have been used in clinical laboratory medicine since the 1960s, and are indispensable tools in clinical diagnostics. A wide range...

2014-10-27 08:28:43

PCT-dependent Method Provides High Quality Mass Spectrometry-based Proteomic Analysis in Small Needle Biopsy Samples for the First Time, Offering Potential to Vastly Improve Drug Discovery and Design Programs and Diagnostic Insights in Research and Clinical Laboratories Worldwide SOUTH EASTON, Mass., Oct. 27, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a worldwide leader in the development and sale of high pressure-based sample preparation...

2014-10-22 20:23:21

LONDON, Oct. 22, 2014 /PRNewswire/ -- This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The personalized medicine (global) market is presented as follows: -- By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH)-- By Geography...

2014-10-22 08:33:04

HAMILTON, N.J., Oct. 22, 2014 /PRNewswire/ -- Medical Diagnostic Laboratories, L.L.C., (MDL), a CLIA-certified, CAP-accredited laboratory which specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses, announces that it is now offering new Cystic Fibrosis Testing which utilizes cutting edge technology, including next- generation DNA sequencing platforms. Cystic fibrosis (CF), or mucoviscidosis, is a genetically inherited multisystem disorder that...

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents for the treatment of HER2-positive breast cancer and EGFR-mutation positive metastatic, non-small-cell lung cancer (NSCLC). However,...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.